BARROW NEUROLOGICAL INSTITUTE
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Speech Analysis in ALS Patients
- Conditions
- ALSLou Gehrig DiseaseAmyotrophic Lateral Sclerosis
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Barrow Neurological Institute
- Target Recruit Count
- 26
- Registration Number
- NCT03868345
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
Deep Phenotyping in Patients With ALS
- Conditions
- ALSMotor Neuron Disease
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Barrow Neurological Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02819765
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸Hospital for Special Surgery (HSS), New York, New York, United States
A Trial of Tocilizumab in ALS Subjects
- Conditions
- Motor Neuron DiseaseALSLou Gehrig's DiseaseAmyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Barrow Neurological Institute
- Target Recruit Count
- 22
- Registration Number
- NCT02469896
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Barrow Neurological Institute
- Target Recruit Count
- 52
- Registration Number
- NCT01938495
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸California Pacific Medical Center, San Diego, California, United States
News
XPro™ Shows Promise in Reducing Alzheimer's Pathology Following Traumatic Brain Injury in Preclinical Study
INmune Bio's XPro™ (XPro1595, pegipanermin) significantly reduced amyloid formation and improved brain function in transgenic mice following traumatic brain injury.
Pridopidine Shows Promise for ALS Subgroups in Healey Platform Trial
Pridopidine demonstrated safety and potential efficacy in secondary endpoints for ALS patients, particularly improving motor speech performance, despite not meeting the primary endpoint in the Healey Platform Trial.
NeuroSense to Present Promising Phase 2b Data for Novel ALS Drug PrimeC at AAN Meeting
NeuroSense Therapeutics will showcase new data from PrimeC's Phase 2b trial in ALS at the American Academy of Neurology Meeting on April 8, 2025, featuring presentations on clinical outcomes and microRNA biomarker findings.
Leading Neuro-Oncologist Emphasizes Importance of Proactive Mentorship in Brain Cancer Research
Dr. Yoshie Umemura, Chief Medical Officer at Ivy Brain Tumor Center, advocates for aspiring neuro-oncologists to actively seek mentors beyond their institutions to advance in the field.
Niraparib Shows Promise in Extending Survival for Glioblastoma Patients in Clinical Trials
The Ivy Brain Tumor Center is conducting Phase 3 clinical trials of Niraparib, a targeted therapy, for Glioblastoma (GBM) patients.